Full-Time

Clinical Manager

Product Training and Education, Urology & Critical Care

Updated on 8/23/2026

Becton Dickinson

Becton Dickinson

10,001+ employees

Global medical devices and diagnostics provider

No salary listed

Seattle, WA, USA + 1 more

More locations: Portland, OR, USA

Remote

Travel may be up to 80%, including driving, flying, and overnight stays.

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Patient Care
Word/Pages/Docs
Salesforce
Excel/Numbers/Sheets

Get referred to Becton Dickinson

See people who can refer or advise you

Requirements
  • A college degree or equivalent is required.
  • A Registered Nurse license is required and must be maintained.
  • At least three years of patient care experience is required.
  • Experience in hospital intensive care, critical care, emergency department, leadership roles, committee participation, or charge nurse work is advantageous.
  • The ability to function independently with minimal guidance or supervision is required.
  • Strong listening, communication, interpersonal, relationship-building, organizational, and multitasking skills are required.
  • The ability to work effectively in a sales environment and with a sales team is required.
  • The ability to collect, analyze, and present clinical data is required.
  • Proficiency with Microsoft Word, PowerPoint, Excel, and computers is required.
  • The ability to assess problems, overcome objections, solve practical problems, and interpret written or oral instructions is required.
  • A valid state-issued driver's license and compliance with BD's auto safety standards are required.
  • The employee must be able to perform the stated physical duties, including sitting, bending, stooping, keyboard use, seeing, talking, hearing, prolonged standing, and occasionally lifting up to 50 pounds.
  • The employee must be able to work variable schedules and multiple shifts when necessary.
  • The position requires work in hospitals and a home-based office.
Responsibilities
  • Coordinate and administer all aspects of ongoing and future product training programs, including planning, organizing, leading, and maintaining program activities.
  • Ensure customers have the opportunity to complete Bard product training.
  • Partner with sales and marketing to meet company sales goals.
  • Deliver live and electronic training programs according to company compliance standards.
  • Train internal customers, including territory managers, district managers, marketing, regulatory, and internal training and education teams.
  • Train external customers, including current and potential Bard customers, professional organizations, and key opinion leaders.
  • Conduct product training assessments, including collecting information about Bard product use, analyzing information, presenting findings, and delivering training.
  • Plan program delivery in accordance with Bard Medical's mission and goals.
  • Carry out new initiatives supporting the organization's strategic direction.
  • Use the program evaluation framework to assess program strengths and identify areas for improvement.
  • Maintain forms and records documenting program activities in Salesforce.
  • Oversee collection and maintenance of program records for statistical purposes in accordance with confidentiality and privacy policies.
  • Communicate with stakeholders to gain program support and solicit input for improvement.
  • Liaise with hospital leadership to ensure effective and efficient program delivery.
  • Develop product training plans, including hospital team members as needed.
  • Coordinate service delivery among program activities to increase effectiveness and efficiency.
  • Monitor program activities regularly and conduct annual assessments according to the AIM program framework.
  • Maintain the personal travel budget as part of the Training Specialist team budget.
  • Maintain the ICC budget.
  • Schedule time in accounts with the sales partner and use time efficiently.
  • Maintain knowledge and expertise as a product specialist for the Bard Medical product line, focusing on urological drainage and stool management.
  • Establish and maintain positive working relationships with internal and external stakeholders.
  • Develop new ways to improve organizational operations and create opportunities.
Desired Qualifications
  • Experience using and teaching the use of Bard products.

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Get referred to Becton Dickinson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
  • Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
  • Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.

What critics are saying

  • FDA classified BD’s intraosseous recall Class I on August 17, 2026.
  • The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
  • Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.

What makes Becton Dickinson unique

  • BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
  • BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
  • BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
Yahoo Finance
Aug 18th, 2026
Wall Street analysts give Becton, Dickinson a 'moderate buy' rating despite 12% earnings decline forecast

Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".

PR Newswire
Aug 17th, 2026
BD names Gary Sorsher chief quality officer as Jeff Silvestri retires after 25 years

BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.

MedTech Dive
Aug 13th, 2026
BD fully enrolls trial of resorbable mesh for hernia prevention.

BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."

Yahoo Finance
Aug 9th, 2026
BD up 6.8% on Q3 beat, GLP-1 pen partnerships boost biologic delivery outlook

Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.

Yahoo Finance
Aug 7th, 2026
BD reports Q3 fiscal 2026 results with $5B revenue up 5.4% and adjusted EPS of $3.23

BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.